Lessons from therapeutic failure in HER2+ BC have demonstrated that while ligand-independent HER2 signaling can be successful with Herceptin, the same inhibitory drug remains ineffective in the ligand-dependent signaling scenario. Here, ERBB2 is linked to breast cancer.